Microbiological Activity and Clinical Efficacy of a Colistin and Rifampin Combination in Multidrug-Resistant Pseudomonas aeruginosa Infections

REFERENCES

• Burwen DR, Banerjee SN, Gaynes RP and the National Nosocomial Infections Surveillance System. Ceftazidime resis-tance among selected nosocomial gram negative bacilli in the United States. J Infect Dis 1994; 170: 1622–5.
   Google Scholar
• Gerding DN, Larson TA, Hughes LA et al. Aminoglycoside resistance and aminoglycoside usage: ten years of experience in one hospital. Antimicrob Agents Chemother 1991; 35: 1284-90.
   Google Scholar
• Saiman L, Mehar F, Niu WW et al. Antibiotic suscepti-bility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin Infect Dis 1996; 23: 532–7.
   Google Scholar
• Cappelletty DM, Rybak MJ. Comparison of methodolo-gies for synergism testing of drug combinations against resis-tant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1996; 40: 677–83.
   PubMed Web of Science ®Google Scholar
• Baltch AL, Bassey MC, Hammer RP, et al. Synergy with cefsulodin or piperacillin and three aminoglycosides or aztreonam against aminoglycoside resistant strains of Pseudomonas aeruginosa. J Antimicrob Chemother 1991; 27: 801–8.
   PubMed Web of Science ®Google Scholar
• Chin NX, Neu HC. Synergy of new C-3 substituted cephalosporins and tobramycin against Pseudomonas aerugi-nosa and Pseudomonas cepacia. Diagnost Microbiol Infect Dis 1992; 12: 343–9.
   Web of Science ®Google Scholar
• Tascini C, Menichetti F, Bozza S, Del Favero A, Bistoni F. Evaluation of the activities of two-drug combinatios of rifampin, polymyxin B and ampicillin/sulbactam against Acinetobacter baumannii. J Antimicrob Chemother 1998; 42: 270–1.
   PubMed Web of Science ®Google Scholar
• Tascini C, Ferranti S, Messina F, Menichetti F. In vitro and in vivo synergistic activity of colistin, rifampin and amikacin against a multidrug resistant Pseudomonas aerugi-nosa isolate. Clin Microbiol Infect 2000; 6: 690–1.
   PubMed Web of Science ®Google Scholar
• Levin AS, Barone AA, Penco J, et al. Intravenous col-istin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter bau-mannii. Clin Infect Dis 1999; 28: 1008–11.
   PubMed Web of Science ®Google Scholar
• Thornsberry C, Hill BC, Swenson JM, McDougal LK. Rifampin: spectrum of antibacterial activity. Rev Infect Dis 1983; 5: S412–7.
   PubMedGoogle Scholar
• National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests, 6th. ed. Approved guideline. Document M2-A6. National Committee for Clinical Laboratory Standards, Villanova, Pa, 1997.
   Google Scholar
• Gales AC, Reis AO, Jones RN. Contemporary assess-ment of antimicrobial susceptibility testing methods for polymyxyn B and colistin: review of available interpretative cri-teria and quality control guidelines. Antimicrob Agents Chemother 2001; 39: 183–90.
   Google Scholar
• National Committee for Clinical Laboratory Standards. Performance standard for antimicrobial susceptibility testing. Document M100-S10. National Committee for Clinical Laboratory Standards, Villanova, Pa, 2000.
   Google Scholar
• National Committee for Clinical Laboratory Standards. Methods for determining bactericidal activity of antimicrobial agents. Approved guideline. Document M26-P. National Committee for Clinical Laboratory Standards, Villanova, Pa, 1987.
   Google Scholar
• Marques MB, Brookings ES, Moser A, et al. Comparative in vitro antimicrobial susceptibilities of nosocomial isolates of Acinetobacter baumannii and synergistic activi-ties of nine antimicrobial combinations. Antimicrob Agents Chemother 1997; 41: 881–5.
   PubMed Web of Science ®Google Scholar
• Cappelletty DM, Rybak MJ. Comparison of methodolo-gies for synergism testing of drug combinations against resis-tant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1996; 40: 677–83.
   PubMed Web of Science ®Google Scholar
• Evans ME, Feola DJ, Rapp RP. Polymyxin B sulphate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother 1999; 33: 960–967.
   PubMed Web of Science ®Google Scholar
• Paterson DL, Cornaglia G, Mazzariol A, Lamonaca V, Gruttadauria S, Marino I. A true return to the pre-antibiotic era? Endovascular infections as sequelae of bacteremia with Pseudomonas aeruginosa producing VIM-1, resistant to car-bapenems, chephalosporins, penicillins, quinolones and aminoglycosides. In Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, MI, 2002. Abstract K1183, p. 406. American Society for Microbiology, Washington, DC.
   Google Scholar
• MacGowan AP, Rynn C, Wootton M, Bowker KE, Holt HA, Reeves DS. In vitro assessment of colistin's antimicrobial interactions with six other antimicrobials studied using a repre-sentative strain of P. aeruginosa. Clin Microbiol Infect 1999; 5: 37–46.
   PubMedGoogle Scholar
• Vaara M. The outer membrane permeability-increasing action of linear analogues of polymyxin B nonapeptide. Drug Exp Clin Res 1991; 17: 437–43.
   PubMedGoogle Scholar
• Linden PK, Kuene S, Coley K, Fontes P, Kramer DJ, Paterson D. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis 2003; 37: 154–160.
   PubMed Web of Science ®Google Scholar
• Hilf M, Yu VL, Sharp J, et al. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 1989; 87: 540–546.
   PubMed Web of Science ®Google Scholar
• Rynn C, Wootton M, Bowker KE et al. In vitro assess-ment of colistin's antipseudomonal antimicrobial interactions with other antibiotics. Clin Microbiol Infect 1999; 5: 32–36.
   Google Scholar
• Giamarellou-Barboulis EJ, Sambatakou H, Galani I et al. In vitro interaction of colistin and rifampin on multidrug-resistant Pseudomonas aeruginosa. J Chemother 2003; 15: 235–238.
   Google Scholar